GSK 2981278
CAS No. 1474110-21-8
GSK 2981278( GSK2981278 | GSK-2981278 )
Catalog No. M12032 CAS No. 1474110-21-8
GSK 2981278 (GSK2981278) is a potent, highly selective RORγ/RORγt inhibitor that potently inhibits IL-17A and IL-22 protein secretion in human peripheral T cell with IC50 of 3.2 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 70 | In Stock |
|
| 10MG | 106 | In Stock |
|
| 50MG | 302 | In Stock |
|
| 100MG | 448 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK 2981278
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK 2981278 (GSK2981278) is a potent, highly selective RORγ/RORγt inhibitor that potently inhibits IL-17A and IL-22 protein secretion in human peripheral T cell with IC50 of 3.2 nM.
-
DescriptionGSK 2981278 (GSK2981278) is a potent, highly selective RORγ/RORγt inhibitor that potently inhibits IL-17A and IL-22 protein secretion in human peripheral T cell with IC50 of 3.2 nM; shows no effects on RORα-dependent activation; robustly inhibits RORγ-mediated cytokine production at both the mRNA and protein level, inhibits RORγt-mediated transactivation; attenuates inflammation in mouse model of psoriasis.Psoriasis Phase 2 Clinical(In Vitro):GSK2981278 markedly and potently inhibits IL-17A and IL-22 protein secretion in a concentration dependent manner (IC50 = 3.2 nM) during 5 days of culture under Th17 skewing conditions.GSK2981278 (0.3, 1, 3, 10, 30, 100, 300, 1000 pM; 5 day) potently and selectively inhibits IL-17 and IL-22 levels. Culture in the presence of ≥3 nM GSK2981278 led to a near-complete inhibition of IL-17A protein secretion.(In Vivo):GSK2981278 (1% in ointment; topically; for three days) reduces skin redness and scaling, as well as decreased hyperplasia, as evidenced by a 23% reduction in epidermal thickness. GSK2981278 attenuates inflammation in a mouse model of psoriasis.
-
In Vitro——
-
In VivoAnimal Model:BALB/c JByRj Female Mice (8 week-old at study initiation; imiquimod (IMQ) mouse model) Dosage:1% Administration:In ointment; topically; for three days Result:Reduced skin redness and scaling, as well as decreased hyperplasia, as evidenced by a 23% reduction in epidermal thickness.
-
SynonymsGSK2981278 | GSK-2981278
-
PathwayNuclear Receptor/Transcription Factor
-
TargetROR
-
RecptorRORγ
-
Research AreaInflammation/Immunology
-
IndicationPsoriasis
Chemical Information
-
CAS Number1474110-21-8
-
Formula Weight461.617
-
Molecular FormulaC25H35NO5S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM ( < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESO=S(C1=CC=C(OCC2CCOCC2)C(CO)=C1)(N(C3=CC=C(CC)C=C3)CC(C)C)=O
-
Chemical NameN-(4-Ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)methoxy]benzenesulfonamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kang EG, et al. Br J Dermatol. 2017 Nov 18. doi: 10.1111/bjd.16131.
2. Smith SH, et al. PLoS One. 2016 Feb 12;11(2):e0147979.
molnova catalog
related products
-
SR2211
SR2211 is a specific modulator and an inverse agonist of RORγ(IC50 = 320 nM, Ki = 105 nM).
-
Bevurogant
Bevurogant is an antagonist of RORγt receptor and can be used in studies about the treatment of chronic inflammatory diseases.
-
RORγt inverse agonis...
RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist (IC50=63.8 nM), with improved drug-like properties.
Cart
sales@molnova.com